Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Jumps On Positive News

After the initial upward run the stock of Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) made in the beginning of the month, things quickly turned sour and the ticker has been sliding down the charts in the past 2 weeks of trading.

Yesterday, however, the company announced that it has entered into a worldwide license agreement with the University of Massachusetts Medical School for intellectual property that will allow exclusive use of mesencephalic astrocyte-derived neurotrophic factor (MANF) both as treatment for beta cell-degenerating disorders and a biomarker.

This was enough to provide some investor interest and a good 15% gain in price. At the end of the day AMBS closed with a price of $0.052, while 5.9 million shares switched hands and in term generated $316 thousand in dollar volume.

It looks like the company stock is taking a breath of fresh air, but will it manage to keep the upward trend. Considering the fact that we regularly see optimistic news from AMBS we think that there is a possibility that this was a one-day gain and the stock might return to the overall downward direction it has had in a while.

On the good side of things AMBS‘s cash reserves have increased quite a lot in the last reported period, as well as their assets. The losses, however, continue to grow, so the ticker is rather unpredictable.

In any case be sure to do a lot of due diligence and weigh out the risks if you have any thoughts of taking the bet with AMBS.

Provectus Pharmaceutical Inc (OTCMKTS:PVCT) also had a decent session yesterday after 2 days in the red and added 16% to its value. Axion International, Inc. (OTCBB:AXIH) was not so fortunate and registered a third session in a southern direction with a 14% loss.